Key Takeaways
- Worst quarter, but floor called: Revenue fell 15% YoY on a 26% realization drop, and management explicitly labeled Q1 the worst quarter since inception, while signaling that high-cost inventory pain is now behind them.
- Volume engine still running: Volume grew 11% YoY as new CPVC and epichlorohydrin capacity came online, and the downstream mix jumped from 21% to 38% of revenue, validating the diversification thesis even in a downcycle.
- Margin recovery is a second-half story: EBITDA and PAT de-grew sharply on realization pressure and high-cost inventory; management sees improvement starting Q3 and guided full-year absolute EBITDA of Rs. 450–500 crores.
- Destocking nearing its end: Management believes the destocking cycle that crushed exports is almost done and expects the narrative to fade by early H2, with pockets of demand already stirring in domestic textiles and pharma.
- What to watch next quarter: Whether realizations actually bottomed in Q1, the pace of CPVC and ECH ramp-up toward optimum levels by Q3, and any confirmation that export destocking has flipped to restocking.
The Downcycle: Realization, Inventory & Demand
- Realization collapse: Realization dropped around 26% YoY, far outpacing the softening in raw material costs, which squeezed margins across the board. Management called Q1 the worst quarter since manufacturing began and insisted it will not stay this way forever.
- High-cost inventory hit done: The quarter carried the weight of high-cost glycerin, PVC, and coal inventory that lagged the fall in chemical prices. Management stated this impact is now complete and only minor changes will follow from Q2 onward.
- Demand split: Domestic demand is showing early green shoots in pharma, agrochemicals, specialty chemicals, and textiles, with the festive season starting to pull. Export demand remains very low, though destocking is expected to give way to restocking by September.
- Overcapacity absorption: Management acknowledged short-term excess capacity in chlor alkali and ECH but argued it will be absorbed in 6–9 months, drawing parallels to prior cycles in 2010 and 2014.
Maulik Patel: "Quarter 1 is going to be, I think, the worst quarter since we have started manufacturing. It is not going to remain the same forever."
Diversification Payoff: Downstream Mix Shift
- Structural shift in revenue: Derivatives and specialty chemicals contributed 38% of revenue in Q1 versus 21% a year ago, driven by new CPVC, epichlorohydrin, and hydrogen peroxide capacity. This mix shift is the core of the company's margin-resilience argument.
- Derivatives now more profitable than chlor alkali: In the current depressed environment, profitability from derivatives ran higher than from chlor alkali, validating the thesis that downstream products deliver more sustainable and consistent margins. In normal times, chlor alkali margins sit at 25–28%.
- Product-level opacity: Management declined to break out turnover or margins by individual downstream product, leaving investors unable to assess which derivatives are carrying the portfolio.
- ECH ramp slower than hoped: Domestic and export ECH volumes are growing quarter-on-quarter but at a pace slower than expected; management still targets reaching optimum utilization by Q3.
Margins & Profitability: The Walk to Recovery
- FY24 absolute EBITDA guided to Rs. 450–500 crores: Management provided this range as the full-year expectation, implying a significant second-half recovery from the Q1 trough.
- Margin trajectory: Things have started improving, but the benefit will likely land in Q3 onward. The full-year EBITDA margin is expected around 25–26%, with upside if the second half strengthens.
- Inventory loss overhang cleared: Most chemical companies took the inventory hit in Q4 or Q1; from July, a couple of raw materials have started moving upward, and no major inventory loss is expected from Q2.
- Longer-term aspiration: Management is targeting 28% EBITDA margin plus or minus and 25% pre-tax ROCE, anchored to the expansion plan and downstream mix shift.
Expansion Pipeline: Volume Growth Levers
- CPVC expansion on track: The 45,000 tonnes per annum CPVC expansion will commission by Q4 FY24 and start reflecting in the balance sheet from the beginning of that quarter, driving volume in both FY24 and FY25.
- Chlorotoluene value chain: On schedule and will begin contributing revenue slowly and gradually from FY25 onward, adding another leg to the specialty chemicals portfolio.
- Revenue target moderated: The Rs. 5,000 crore by 2027 target may land at Rs. 4,500–4,600 crores in a downcycle like the current one, but management believes the expansion and capex plan will get there on a longer-term basis.
- Chlorine integration deepening: In-house chlorine consumption is expected to reach around 75% in 1.5–2 years, with an eventual target of 85%, reducing merchant chlorine exposure.
Maulik Patel: "You are right that the time when we have finalized the Rs. 5,000 crores, it may be here or there. It may not be exact Rs. 5,000 crores. Sometimes in down cycle like current situation, it may be Rs. 4,500 crores or Rs. 4,600 crores kind of thing. But yes, normally on a longer-term point of view, we believe that we will achieve those numbers."
Competitive Position & Market Structure
- Cost-position confidence: Management asserted that MFL's integrated input costs and built infrastructure make it the last player to lose money in a downturn, even if everyone else is losing.
- Caustic soda breakeven revealed under pressure: After initial deflection, management pegged industry breakeven cost for caustic soda at Rs. 24,000–25,000 per ton, though noted this depends on integration levels.
- ECH imports persist: Thai ECH imports continue due to long-standing relationships, even as Indian capacity expands. Management expects its own market share to increase much faster as domestic demand grows.
- Caustic demand tailwind: Alumina capacity expansion in India is expected to lift caustic soda demand 2–3 years out.
B Ravi: "as far as MFL is concerned, the kind of an input cost that they have and the infrastructure they already have built and integrated, they will be the last one to be losing. Even if everybody else loses, they will be the last to lose."
Energy & Infrastructure
- Hybrid power plant live: An 18.34 MW hybrid power plant was commissioned in Q1, contributing to P&L through the price differential with grid power and marking a step toward green energy.
- Green energy ceiling: Management stated the chemical industry cannot afford more than 30–40% green energy in its mix, as 100% green baseload is not feasible for continuous-process plants.
- R&D center near completion: The R&D center is almost ready and positioned as a pillar for future growth in specialty chemicals.
- Export logistics milestone: The company sailed its first vessel to Europe last quarter and its first vessel to the US in the current quarter, expanding its global reach.
Maulik Patel: "But now onwards, I think in the future, I would say at least you can invest up to 30% to 40% of your requirement by green energy, not more than that. None of the industry can afford 100% on the green base possible. It is not possible in the chemical industry, at least."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Full-year absolute EBITDA | Rs. 450–500 crores | FY24 |
| Debt to EBITDA | Remain less than 2x | Ongoing |
| CPVC expansion commissioning | 45,000 TPA capacity online | Q4 FY24 |
| ECH utilization | Reach optimum level | Q3 FY24 |
| Chlorotoluene revenue start | Slow and gradual contribution begins | FY25 |
| Revenue target | Rs. 5,000 crores (may be Rs. 4,500–4,600 crores in downcycle) | By 2027 |
| EBITDA margin aspiration | 28% plus or minus | Longer-term |
| Pre-tax ROCE aspiration | 25% | Longer-term |
| In-house chlorine consumption | Reach ~75% | 1.5–2 years |
Key Metrics
| Metric | Q1 FY24 |
|---|---|
| Revenue | Down 15% YoY, realization down ~26% YoY, volume up 11% YoY |
| Revenue from derivatives and specialty chemicals | 38% of total revenue, up from 21% in Q1 FY23 |
| EBITDA (absolute, FY24 guidance) | ₹450–500 cr expected for full year FY24 |
| EBITDA margin (FY24 guidance) | ~25–26% expected for full year; Q3 onwards improvement anticipated |
| PAT | De-grew YoY, impacted by lower realizations and high-cost inventory consumption |
| Trailing 12-month ROCE | 25% as on 30 June 2023 |
| Trailing 12-month ROE | 29% as on 30 June 2023 |
| Net debt | ₹902 cr as on 30 June 2023, versus ₹863 cr as on 31 March 2023 |
| Net debt to EBITDA | 1.5x in Q1 FY24, versus 1.3x in Q4 FY23 |
| Net debt to equity | 0.8x in Q1 FY24 |
| CAPEX spend | ₹108 cr in Q1 FY24 |
| Overall plant capacity utilization | ~70% |
| Caustic soda capacity utilization | ~70–75% |
| Caustic soda ECU realization | ~₹30,500 per ton |
| Caustic soda realization change | Dropped ~40% YoY |
| Chlorine consumption in-house | ~65%, targeting 75% in 1.5–2 years, eventually 85% |
| CPVC Indian market size | ~2,25,000 tonnes per annum, growing at double digits |
| CPVC Indian manufacturing capacity | 40 KTPA, expanding to 75 KTPA |
| Revenue target by 2027 | ₹5,000 cr |
| Pre-tax ROCE target | 25% |
| Debt to EBITDA expected range | Less than 2x |
| FY24 debt repayment | ~₹240 cr |
| Hybrid power plant commissioned | 18.34 MW in Q1 FY24 |